echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hongri Pharmaceutical Co., Ltd. obtains FDA approval for the treatment of sepsis with picrocramide B mesylate for injection

    Hongri Pharmaceutical Co., Ltd. obtains FDA approval for the treatment of sepsis with picrocramide B mesylate for injection

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 19, Hongri Pharmaceuticals issued an announcement stating that the company had recently received a request from the US FDA regarding the consent for injection of Chrysene Chrysene B (CHS-201) (hereinafter referred to as "KB") for the treatment of sepsis.


    In June 2014, KB was approved and issued by the National Medical Products Administration "Drug Clinical Trial Approval" (Lot No.


    After obtaining the US FDA clinical trial qualification this time, KB's phase II clinical research plan for the treatment of patients with sepsis will be carried out in the United States


    KB is a dual-target bacterial pathogen-related molecular antagonist, which treats sepsis by neutralizing bacterial endotoxin and bacterial genomic DNA, blocking or reducing the occurrence of inflammation


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.